Table.
Clinical, transplant, and vaccination characteristics of solid organ transplant recipients who received tixagevimab and cilgavimab.
| N | 36 |
|---|---|
| T+C dose, n (%) | |
| 2 150 + 150 doses | 13 (36%) |
| 1 300 + 300 dose | 23 (64%) |
| Age (y), median (IQR) | 60.7 (58.1, 66.1) |
| Transplanted organ(s), n (%) | |
| Kidney | 20 (56%) |
| Liver | 3 (8%) |
| Lung | 5 (14%) |
| Heart | 4 (11%) |
| Multiplea | 4 (11%) |
| Sex, n (%) | |
| Male | 16 (44%) |
| Female | 20 (56%) |
| Race, n (%) | |
| White | 33 (92%) |
| Other | 3 (8%) |
| Years since transplant, median (IQR) | 4.1 (1.7, 9.2) |
| Maintenance immunosuppression, n (%) | |
| Triple immunosuppressionb | 19 (53%) |
| Mycophenolate | 30 (83%) |
| Corticosteroids | 23 (64%) |
| Calcineurin inhibitor | 30 (83%) |
| mTOR inhibitors | 6 (17%) |
| Belatacept | 1 (3%) |
| Number of vaccine doses prior to T+C, n (%) | |
| 3 | 8 (22%) |
| 4 | 27 (75%) |
| 5 | 1 (3%) |
| Days from last vaccination to T+C, median (IQR) | 38.5 (26, 114.5) |
| History of prior COVID-19c, n (%) | 2 (6%) |
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range; mTOR, mammalian target of rapamycin inhibitor; T+C, tixagevimab and cilgavimab.
a
Includes heart-kidney (1), liver-kidney (1), and kidney-pancreas (2).
b
Defined as corticosteroids plus calcineurin or mTOR inhibitor plus antimetabolite.
c
Defined as self-reported prior to a positive COVID-19 test or baseline (pre-T+C)-positive antinucleocapsid antibody.